FIZE Medical Raises $20M Series B Led by Asahi Kasei Medical

FIZE Medical, an Israel-based medtech company, has raised $20 million in Series B funding. The round was led by Asahi Kasei Medical, with participation from Rapha Capital Management.

What FIZE Medical Does

FIZE Medical builds an AI-powered fluid-management platform for critically ill patients. Its flagship product, the FIZE kUO system, provides continuous, real-time urine-output monitoring to support precision fluid management and earlier detection of acute kidney injury.

The FIZE kUO system is commercially available in Japan, Europe and the United States.

Beyond its current commercial platform, the company is developing FIZE Optima, a next-generation platform designed to predict fluid-related risks and guide treatment decisions with AI.

The Round at a Glance

Company: FIZE Medical
Round type: Series B
Amount raised: $20,000,000
Currency: USD
Announced: September 17, 2026
Lead investor: Asahi Kasei Medical
Additional investors: Rapha Capital Management

Why This Matters for the Medtech Landscape

FIZE Medical sits at the intersection of two durable trends in critical care: the push toward continuous, data-driven patient monitoring, and the growing role of AI in clinical decision support. Its kUO system addresses urine-output monitoring, a core input for fluid management in critically ill patients and a key signal in the detection of acute kidney injury.

The company's commercial footprint already spans three major markets — Japan, Europe and the United States — giving it a multi-region revenue base rather than a single-market launch story. That breadth is notable for a company at the Series B stage.

The development pipeline adds a second layer to the thesis. FIZE Optima is positioned as a next-generation platform intended to predict fluid-related risks and guide treatment decisions with AI, extending the company's scope from monitoring into prediction and decision support.

Investor Signal

The round is led by Asahi Kasei Medical, a strategic investor in the medical space, with Rapha Capital Management also participating. A strategic lead at the Series B stage can signal alignment between the company's clinical roadmap and the priorities of an established healthcare player.

What to Watch

Commercial expansion of the FIZE kUO system across its existing markets in Japan, Europe and the United States.
Progress on FIZE Optima and its AI-driven prediction and treatment-guidance capabilities.
How the company deploys the $20 million toward scaling its fluid-management platform.

For those tracking medtech M&A and strategic investment, FIZE Medical represents a company with an already-commercialized core product, a multi-market footprint, and a clearly articulated next-generation platform in development — a combination that tends to draw attention from both strategic and financial acquirers.